Johnson & Johnson
Non-Small Cell Lung Cancer
Johnson & Johnson
Results From a Phase 3 Trial of an Innovative Combination Therapy for EGFR+ mNSCLC
FEATURING
Martin Dietrich
- 3 views
- October 23, 2025
Johnson & Johnson
Proactive Management of Dermatologic Adverse Reactions for Patients on an EGFR+ mNSCLC Therapy
FEATURING
Amanda Edmond
- 3 views
- October 31, 2025
Johnson & Johnson
Proactive Therapy Management of Infusion-Related Reactions in Patients Receiving Treatment for mNSCLC
FEATURING
Jun Zhang
- 2 views
- October 27, 2025
Johnson & Johnson
Advancing Care With a 1L Treatment Option for EGFR+ mNSCLC
FEATURING
Mark Andolina
- May 20, 2026